| Trial ID: | L0298 |
| Source ID: | NCT03145623
|
| Associated Drug: |
Elbasvir And Grazoprevir
|
| Title: |
Retrospective Efficacy and Safety Study With Elbasvir/Grazoprevir in HCV-infected Patients With Chronic Kidney Disease
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Hepatitis C|Chronic Kidney Diseases
|
| Interventions: |
DRUG: Elbasvir and Grazoprevir
|
| Outcome Measures: |
Primary: Efficacy of Elbasvir (EBR)/Grazoprevir (GZR), Describe the real life efficacy (Sustained Virologic Response SVR 12) of EBR 50 mg/GZR 100 mg based therapy by assessment of the HCV RNA, 12 weeks after the end of all study therapy | Secondary: Safety during treatment, Assessment of all Adverse Events and laboratory tests collected during treatment, during treatment
|
| Sponsor/Collaborators: |
Sponsor: University Hospital, Toulouse | Collaborators: MSD France
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
100
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2017-06-02
|
| Completion Date: |
2017-12-31
|
| Results First Posted: |
|
| Last Update Posted: |
2018-02-15
|
| Locations: |
University Hospital, Caen, 14000, France|University Hospital Toulouse, Toulouse, 31059, France
|
| URL: |
https://clinicaltrials.gov/show/NCT03145623
|
